An alert launched on three anticoagulant drugs

An alert launched on three anticoagulant drugs

Health authorities are concerned about the dangers that three new generation anticoagulants, Eliquis, Pradaxa and Xarelo, could pose to public health. Appeared in 2008, these drugs prescribed to prevent the risk of stroke can cause serious bleeding.

Biologists are
worried and have just written to the Minister of Health, Marisol Touraine, to
alert him to the dangers of three new oral anticoagulants (NACO).

The drugs in question – Eliquis, Pradaxa and Xarelot – appeared in France five years ago and are prescribed for coagulation problems: embolisms, heart attacks, phlebitis,
Stroke.

The problem for health professionals who expressed their concerns in a letter released last week by the Medicines Agency (ANSM) is that these new generation products present “bleeding risk factors “.

Until now, patients exposed to the risk of blood clots took a well-known anticoagulant:
the Previscan. Effective, it had the disadvantage of requiring heavy monitoring,
know a blood test every 15 days.

In 2008, a
new molecule that does not require
this follow-up, the Pradaxa. Doctors began to prescribe it en masse. But this drug is not without danger. The journalist from France News Mathilde Lemaire thus met Roger, 84, a user of the drug and who had internal bleeding.

According to the union of young medical biologists (SJBM), cases like his are numerous, sometimes with a fatal outcome. The old treatment could also cause bleeding.

But big difference, the new generation anticoagulants have no antidote to be injected urgently in case of problem. The SJBM announced on Friday that it had written a letter to the Minister of Health to “sound the alarm “.

The old treatment cost 12.50
euros per month. The new one costs 70 euros. Therefore, some people wonder
as to the possible pressure exerted by pharmaceutical companies which would incite
to prescribe the new molecule.

For the moment, there is no question of calling into question the marketing of the products concerned, even if they have been placed on the list of medicines under ANSM surveillance.

Leave a Reply

Your email address will not be published.